Generic placeholder image

Current Pharmaceutical Design


ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles

Author(s): Qiu Zhang and Fei Li

Volume 19, Issue 37, 2013

Page: [6655 - 6666] Pages: 12

DOI: 10.2174/1381612811319370009

Price: $65


The development of multidrug resistance (MDR) to chemotherapy is a major obstacle for the successful treatment of cancer. A number of mechanisms have been postulated to account for MDR in cancer. The most common and best-studied mechanism of resistance is mediated through the drug efflux protein P-glycoprotein (P-gp), which is overexpressed in drug-resistant cancer cells and is responsible for the removal of many chemotherapeutic agents. Therapeutic nanoparticles (NPs) have emerged as an innovative and promising option to combat P-gp-mediated MDR and have shown enhanced therapeutic efficacy and reduced toxicity compared to their small molecule counterparts. This review focuses on recent studies using therapeutic NPs to circumvent P-gp-mediated MDR in cancer therapy. The advantages and strategies by which therapeutic NPs were used to overcome P-gp-mediated MDR in cancer are discussed.

Keywords: P-glycoprotein, multidrug resistance, nanotechnology, drug delivery, therapeutic nanoparticles, cancer chemotherapy.

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy